These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8876871)

  • 41. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients.
    Nucci M; Loureiro M; Silveira F; Casali AR; Bouzas LF; Velasco E; Spector N; Pulcheri W
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1445-8. PubMed ID: 10348768
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amphotericin B infusion-related toxicity: comparison of two- and four-hour infusions.
    Nicholl TA; Nimmo CR; Shepherd JD; Phillips P; Jewesson PJ
    Ann Pharmacother; 1995 Nov; 29(11):1081-7. PubMed ID: 8573948
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Acute adverse effects following administration of liposomal amphotericin B].
    Portillo-Cano Mdel M; Lobo-Acosta MA; Ríos-Villegas MJ; Alanís-López J
    Enferm Infecc Microbiol Clin; 2006 May; 24(5):352. PubMed ID: 16762265
    [No Abstract]   [Full Text] [Related]  

  • 44. Activity of amphotericin B in lipid emulsion in the initial treatment of canine leishmaniasis.
    Lamothe J
    J Small Anim Pract; 2001 Apr; 42(4):170-5. PubMed ID: 11327663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients.
    Sorkine P; Nagar H; Weinbroum A; Setton A; Israitel E; Scarlatt A; Silbiger A; Rudick V; Kluger Y; Halpern P
    Crit Care Med; 1996 Aug; 24(8):1311-5. PubMed ID: 8706484
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Successful treatment of cryptococcal meningitis with liposomal amphotericin B (L-AMP-LRC-1) intolerant to conventional amphotericin B.
    Kirodian BG; Virani AR; Kshirsagar NA
    J Assoc Physicians India; 2002 Apr; 50():601-2. PubMed ID: 12164423
    [No Abstract]   [Full Text] [Related]  

  • 47. Lipid emulsion reduces subacute toxicity of amphotericin B: a histopathological study.
    Souza LC; Saldiva PH; Campa A
    Exp Toxicol Pathol; 2000 May; 52(2):169-75. PubMed ID: 10965993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Controlled pilot study of rapid amphotericin B infusions.
    Dele Davies H; King SM; Doyle J; Matlow A; Koren G; Hamilton R; Portwine C
    Arch Dis Child; 1997 Feb; 76(2):165-6. PubMed ID: 9068312
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Controlled trials of amphotericin B lipid complex.
    Boyle JA
    Clin Infect Dis; 2000 Oct; 31(4):1117-8. PubMed ID: 11049803
    [No Abstract]   [Full Text] [Related]  

  • 51. Liposomal amphotericin B for fever and neutropenia.
    Patel MA; Curtis K; Maguire JH
    N Engl J Med; 1999 Oct; 341(15):1153; author reply 1154-5. PubMed ID: 10515752
    [No Abstract]   [Full Text] [Related]  

  • 52. Nephrotoxicity of different formulations of amphotericin B: summarizing evidence by network meta-analysis.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Clin Infect Dis; 2013 Dec; 57(12):1783-4. PubMed ID: 24140972
    [No Abstract]   [Full Text] [Related]  

  • 53. Are there risk factors for acute renal failure in adult patients using deoxycholate amphotericin B?
    Tuon FF; Koenig F; Jacometto D; Rocha JL
    Rev Iberoam Micol; 2013 Jan; 30(1):21-4. PubMed ID: 22995903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting.
    Bes DF; Rosanova MT; Sberna N; Arrizurieta E
    Pediatr Infect Dis J; 2014 Aug; 33(8):e198-206. PubMed ID: 24618932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion.
    Lopez RM; Ayestaran A; Pou L; Montoro JB; Hernandez M; Caragol I
    Am J Health Syst Pharm; 1996 Nov; 53(22):2724-7. PubMed ID: 8931814
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disseminated invasive aspergillosis in a patient with acute leukaemia.
    Gottfredsson M; Steingrímsdóttir H
    Acta Biomed; 2006; 77 Suppl 2():10-3. PubMed ID: 16918060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Generalised toxicoderma secondary to administering liposomal amphotericin B].
    de Miguel-Bouzas JC; Herrero-Poch L; Piñeiro-Corrales G
    Farm Hosp; 2010; 34(4):211-2. PubMed ID: 20638033
    [No Abstract]   [Full Text] [Related]  

  • 58. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
    Singh GP; Saxena RK; Priyadarshy V
    J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comment: compatibility of amphotericin B with lipid emulsions.
    Montoro JB; López RM; Pou L
    Ann Pharmacother; 1996 Dec; 30(12):1501. PubMed ID: 8968472
    [No Abstract]   [Full Text] [Related]  

  • 60. Reversible dilated cardiomyopathy associated with amphotericin B treatment.
    Moyssakis I; Vassilakopoulos TP; Sipsas NV; Perakis A; Petrou A; Kosmas N; Pangalis GA
    Int J Antimicrob Agents; 2005 May; 25(5):444-7. PubMed ID: 15848302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.